MDCO The Medicines Company

28.02
+0.49  (+2%)
Previous Close 27.53
Open 27.53
Price To Book -93.4
Market Cap 2069485833
Shares 73,857,453
Volume 738,708
Short Ratio
Av. Daily Volume 989,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI
Phase 3 trial to be initiated 1H 2018.
Inclisiran
Homozygous familial hypercholesterolemia (HoFH)
Phase 3 sata due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)

Latest News

  1. The Medicines Company to Announce First Quarter 2019 Financial Results on April 25
  2. Medicines Co. (MDCO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  3. Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
  4. Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
  5. Implied Volatility Surging for Medicines Company (MDCO) Stock Options
  6. See what the IHS Markit Score report has to say about Medicines Co.
  7. Alnylam's (ALNY) Impressive Pipeline Drives Share Price
  8. Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
  9. Alnylam Files Application for Hypertension Candidate in UK
  10. Edited Transcript of MDCO earnings conference call or presentation 27-Feb-19 1:30pm GMT
  11. Insider Buys Of The Week: Arconic, CenturyLink, Hain Celestial and More
  12. Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?
  13. If You Had Bought Medicines (NASDAQ:MDCO) Stock A Year Ago, You’d Be Sitting On A 28% Loss, Today
  14. Insider Buying Is Still Alive and Well at These 3 Companies
  15. Alnylam Stock Down Despite Positive Phase III Givosiran Data
  16. Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
  17. Medicines Co (MDCO) Q4 2018 Earnings Conference Call Transcript
  18. The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results